España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Edwards Lifesciences
Biotech In The Earnings Spotlight: Amgen, Celgene, Gilead Sciences
Edwards Lifesciences Gains 8% Following Positive Trial
Market Wrap For May 21: Fed's Minutes Support Wednesday's Bull Run
Edwards Lifesciences Gains 8% Following Positive Trial
Market Wrap For May 21: Fed's Minutes Support Wednesday's Bull Run
Market Wrap For April 22: S&P Rises For Sixth Straight Day, Dow & Nasdaq Also Positive
Market Wrap For April 15: Who Doesn't Love A Turnaround?
Market Wrap For April 22: S&P Rises For Sixth Straight Day, Dow & Nasdaq Also Positive
Market Wrap For April 15: Who Doesn't Love A Turnaround?
Market Wrap For April 14: Markets Surge on Positive Retail Data, Citi Earnings
Market Wrap For December 9: Investors Digest Further Clues Hinting at An Upcoming Taper
Read More...
Edwards Lifesciences Recent News
Medtronic, Snyder's-Lance and Other Stocks Insiders Are Buying
Morgan Keenan Upgrades Edwards Lifesciences from Market Perform to Outperform
Morgan Stanley Gives Color on Edwards Lifesciences After SAPIEN FDA Panel
Piper Jaffray Reiterates Overweight on Edwards Lifesciences
Bank of America Merrill Lynch Maintains Neutral on Edwards Lifesciences
Morgan Stanley Comments on Edwards Lifesciences
Wedbush Reports Solid Q1 Results For Edwards Lifesciences
Wedbush Upgrades Edwards Lifesciences To Neutral, PT To $78
Deutsche Bank Rates Edwards At Hold
Deutsche Bank Raises PT On Edwards Lifesciences To $85
JP Morgan Raises PT On Edwards Lifesciences To $78
Wedbush Raises PT On Edwards Lifesciences To $75
Morgan Stanley Anticipates Rise In EW Share Price
JP Morgan Introduces 2011 Estimates On Edwards Lifesciences
JP Morgan Raises PT On Edwards Lifesciences
Citigroup Maintains Edwards Lifesciences Buy Rating And $79 PT
Edwards Lifesciences Upgraded To Market Perform
PT Changes From RBC Capital
PARTNER B Does Not Disappoint, According to Citi
New PT For Edwards Lifesciences
Deutsche Bank Initiations For 9/10
Deutsche Bank Initiations For 9/10
Credit Suisse Raises Price Target for Edwards Lifesciences (EW)